Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors

International Journal of Cancer

Volumn 133, Issue 4, 2013, Pages 788-796

  Figlin, Robert A ^a   Kaufmann, Isabelle ^b   Brechbiel, Jillian ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Articulate Science   (United Kingdom)

^c Articulate Science   (United States)

Author keywords

mammalian target of rapamycin complex; metastatic renal cell carcinoma; phosphoinositide 3 kinase; resistance; vascular endothelial growth factor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 [4 [1 (1,4 DIOXASPIRO[4.5]DEC 8 YL) 4 (8 OXA 3 AZABICYCLO[3.2.1]OCT 3 YL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 6 YL]PHENYL] 3 METHYLUREA; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ALPHA INTERFERON; APITOLISIB; AXITINIB; AZD 2014; AZD 8055; BEVACIZUMAB; BMK 120; BUPARLISIB; EVEROLIMUS; INK 128; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; XL 147; XL 765;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ASTHENIA; BLEEDING; CARDIOVASCULAR DISEASE; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MULTIPROTEIN COMPLEXES; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84878834146     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28023     Document Type: Review

References (104)

1. Motzer RJ, Agarwal N, Beard C, et al. Kidney cancer. J Natl Compr Canc Netw 2011; 9: 960-77.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
4. Flanigan RC, Campbell SC, Clark JI, et al. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4: 385-90.
5. American Cancer Society. Cancer facts & figures-2012, Atlanta, GA: American Cancer Society, 2012.
6. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-41. (Pubitemid 41702632)
7. Jonasch E, Haluska FG,. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55. (Pubitemid 32155814)
8. Molina AM, Motzer RJ,. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011; 16(suppl 2): 45-50.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Kidney cancer V. 2. 2010.
10. Ljungberg B, Cowan N, Hanbury DC, et al. Guidelines on renal cell carcinoma. Eur Assoc Urol 2010.
11. Rini BI,. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 2010; 16: 1348-54.
12. Rini BI,. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep 2006; 8: 85-9.
13. Kaelin WG, Jr,. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 2009; 115(10 suppl): 2262-72.
14. Rasmussen N, Rathmell WK,. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol 2011; 6: 199-206.
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34. (Pubitemid 46089673)
16. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-8.
17. Nexavar prescribing information. 2011. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/021923s012lbl.pdf. Accessed August 2012.
18. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
19. Sutent prescribing information. 2012. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/021938s019s020lbl.pdf. Accessed August 2012.
20. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8.
21. Votrient prescribing information. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022465s-010S-012lbl. pdf. Accessed August 2012.
22. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-9.
23. Inlyta prescribing information. 2012. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/202324lbl.pdf. Accessed August 2012.
24. Rini BI, Grünwald V, Fishman MN, et al. Axitinib for first-line metastatic renal cell carcinoma (mRCC): overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 2012; 30 (suppl; abstr 4503).
25. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012; 30 (suppl; abstr 4501).
26. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-50.
27. Avastin prescribing information. 2012. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/125085s0238lbl.pdf. Accessed August 2012.
28. Hudes GR,. Targeting mTOR in renal cell carcinoma. Cancer 2009; 115 (suppl 10): 2313-20.
29. Gomez-Pinillos A, Ferrari AC,. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 2012; 26: 483-505.
30. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81. (Pubitemid 46849157)
31. Torisel prescribing information. 2011. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/022088s014lbl.pdf. Accessed August 2012.
32. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
33. Afinitor prescribing information. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022334s017lbl.pdf. Accessed August 2012.
34. Tamaskar I, Dhillon J, Pili R,. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2011; 9: 101-10.
35. Schor-Bardach R, Alsop DC, Pedrosa I, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 2009; 251: 731-42.
36. Rini BI, Atkins MB,. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
37. Dibble CC, Asara JM, Manning BD,. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29: 5657-70.
38. Julien LA, Carriere A, Moreau J, et al. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30: 908-21.
39. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates akt. Cancer Res 2006; 66: 1500-8. (Pubitemid 43259931)
40. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-40. (Pubitemid 46474636)
41. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166: 213-23. (Pubitemid 38988774)
42. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-74.
43. Shah OJ, Wang Z, Hunter T,. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14: 1650-6. (Pubitemid 39239362)
44. Stolovich M, Tang H, Hornstein E, et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol 2002; 22: 8101-13. (Pubitemid 35304044)
45. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 2002; 198: 502-10. (Pubitemid 35447003)
46. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012; 104: 93-113.
47. Elfiky AA, Aziz SA, Conrad PJ, et al. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 2011; 9: 133.
48. Wang S, Jessen K, Kessler L, et al. INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer. Am Assoc Cancer Res Congress 2011;Abstract 4486.
49. Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70: 621-31.
50. Gupta GN, Lin KY, Sourbier C, et al. Preclinical efficacy of AZD8055, an ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor, in vitro in clear cell renal cell carcinoma (RCC). Am Assoc Cancer Res Congress 2011;Abstract 645.
51. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010; 16: 3628-38.
52. Roulin D, Waselle L, Dormond-Meuwly A, et al. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 2011; 10: 90.
53. Peng Q, De P, Dey N, et al. Preclinical studies of a pan PI3K inhibitor (SF1126) in renal cell carcinoma. Am Assoc Cancer Res Congress 2007;Abstract 2378.
54. Garlich J, Su J, Peng X,. Combination effects of sirolimus with the vascular targeted PI3K inhibitor SF1126. Am Assoc Cancer Res Congress 2008;Abstract LB-105.
55. ClinicalTrials.gov. Bevacizumab and BKM-120 in patients with metastatic renal cell carcinoma. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01283048, Accessed August 2012.
56. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-90.
57. Grana B, Burris HA, Rodon Ahnert J, et al. Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29 (suppl; abstr 3043).
58. ClinicalTrials.gov. Safety of BKM120 monotherapy in advanced solid tumor patients. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01068483, Accessed August 2012.
59. ClinicalTrials.gov. A study of BKM120 in adult Japanese patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01283503, Accessed August 2012.
60. ClinicalTrials.gov. BKM120 in cancers with PIK3CA activating mutations. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01501604, Accessed August 2012.
61. ClinicalTrials.gov. BKM120+carboplatin+paclitaxel for patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01297452, Accessed August 2012.
62. ClinicalTrials.gov. PI3K inhibitor BKM120 and docetaxel in treating patients with advanced solid tumor that is locally advanced, cannot be removed by surgery, or metastatic. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01540253, Accessed August 2012.
63. ClinicalTrials.gov. A trial of oral BEZ235 and BKM120 in combination with paclitaxel with or without trastuzumab. Available at: http://www. clinicaltrials.gov/ct2/show/NCT01285466, Accessed August 2012.
64. ClinicalTrials.gov. Safety, pharmacokinetics and pharmacodynamics of BKM120 plus MEK162 in selected advanced solid tumor patients. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01363232, Accessed August 2012.
65. ClinicalTrials.gov. A phase I study of BKM120 and everolimus in advanced solid malignancies. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01470209, Accessed August 2012.
66. ClinicalTrials.gov. Phase ib, dose escalation study of oral LDE225 in combination with BKM120 in patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01576666, Accessed August 2012.
67. ClinicalTrials.gov. BEZ235 in patients with advanced renal cell carcinoma (RCC). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01453595, Accessed August 2012.
68. ClinicalTrials.gov. Dose finding study of RAD001 (everolimus, Afinitor®) in combination with BEZ235 in patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01482156, Accessed August 2012.
69. ClinicalTrials.gov. Study of PI3 Kinase/mTOR inhibitor BEZ235 twice daily for advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT01343498, Accessed August 2012.
70. ClinicalTrials.gov. A study of BEZ235 in adult Japanese patients with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01195376, Accessed August 2012.
71. ClinicalTrials.gov. Safety, pharmacokinetics and pharmacodynamics of BEZ235 plus MEK162 in selected advanced solid tumor patients. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01337765, Accessed August 2012.
72. ClinicalTrials.gov. Safety study of BEZ235 with everolimus in subjects with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT01508104, Accessed August 2012.
73. Burris H, Rodon J, Sharma S, et al. First-in-man phase I study of the oral dual PI3K and mTORC1/2 inhibitor BEZ235 in patients with advanced solid tumors. J Clin Oncol 2010; 28 (abstr 3005).
74. ClinicalTrials.gov. Study of GDC-0980 versus everolimus in patients with metastatic renal cell carcinoma who have progressed on or following vascular endothelial growth factor-(VEGF) targeted therapy. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01442090, Accessed August 2012.
75. Sutherlin DP, Bao L, Berry M, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 2011; 54: 7579-87.
76. Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011; 10: 2426-36.
77. Wagner A, Bendell J, Dolly S, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J Clin Oncol 2011; 29 (abstr 3020).
78. ClinicalTrials.gov. Study of the safety and pharmacokinetics of XL147 (SAR245408) in adults with solid tumors or lymphoma. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00486135, Accessed August 2012.
79. ClinicalTrials.gov. Safety study of XL147 (SAR245408), in combination with paclitaxel and carboplatin in adults with solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00756847, Accessed August 2012.
80. ClinicalTrials.gov. Oral SAR245408 (XL147) and oral MSC1936369B in patients with locally advanced or metastatic solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01357330, Accessed August 2012.
81. ClinicalTrials.gov. Safety study of XL147 (SAR245408) in combination with erlotinib in adults with solid tumors. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00692640, Accessed August 2012.
82. Edelman G, Bedell C, Shapiro G, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28 (suppl; abstr 3004).
83. Traynor AM, Kurzrock R, Bailey HH, et al. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28 (suppl; abstr 3078).
84. ClinicalTrials.gov. Dose escalation study of INK128 in subjects with advanced cancer. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT01058707, Accessed August 2012.
85. ClinicalTrials.gov. Dose escalation study of INK128 in combination with paclitaxel, with/without trastuzumab, in subjects with advanced solid malignancies. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01351350, Accessed August 2012.
86. Tabernero J, Cervantes A, Gordon MS, et al. A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. 2012 American Association for Cancer Research Annual Meeting. Cancer Res 2012; 72 (suppl; abstr nr CT-02).
87. ClinicalTrials.gov. Study of oral OSI-027 in patients with advanced solid tumors or lymphoma. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00698243, Accessed August 2012.
88. Tan DS, Dumez H, Olmos D, et al. First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. 2010 ASCO Annual Meeting. J Clin Oncol 2010; 28 (suppl; abstr 3006).
89. ClinicalTrials.gov. Study to assess the safety and tolerability of the tor kinase inhibitor AZD8055. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00973076, Accessed August 2012.
90. ClinicalTrials.gov. A study of tor kinase inhibitor in advanced tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00731263, Accessed August 2012.
91. ClinicalTrials.gov. Study to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of AZD2014. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01026402, Accessed August 2012.
92. Banerji U, Aghajanian C, Raymond E, et al. First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29 (suppl; abstr 3096).
93. Banerji U, Dean EJ, Gonzalez M, et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. 2012 ASCO Annual Meeting. J Clin Oncol 2012; 30 (suppl; abstr 3004).
94. ClinicalTrials.gov. A dose escalation study of SF1126, a PI3 kinase (PI3K) inhibitor, given by intravenous (IV) infusion in patients with solid tumors (SF112600106). Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00907205, Accessed August 2012.
95. Mahadevan D, Chiorean EG, Harris W, et al. Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29 (suppl; abstr 3015).
96. ClinicalTrials.gov. Study of the safety and pharmacokinetics of XL765 (SAR245409) in adults with solid tumors. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00485719, Accessed August 2012.
97. ClinicalTrials.gov. Safety study of XL765 (SAR245409) in combination with erlotinib in adults with solid tumors. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00777699, Accessed August 2012.
98. LoRusso P, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. 2009 ASCO Annual Meeting. J Clin Oncol 2009; 27 (suppl; abstr 3502).
99. ClinicalTrials.gov. Dose-escalation study of GSK2126458 (FTIH). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00972686, Accessed August 2012.
100. ClinicalTrials.gov. Study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK2126458 and GSK1120212 combination therapy in subjects with advanced solid tumors. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01248858, Accessed August 2012.
101. Munster PN, van der Noll R, Voest EE, et al. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). 2011 ASCO Annual Meeting. J Clin Oncol 2011; 29 (suppl; abstr 3018).
102. Mendez-Vidal MJ, Martinez Ortega E, Montesa Pino A, et al. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012; 31 (suppl 1): 19-27.
103. Coppin C,. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010; 4: 91-101.
104. Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-akt-mTOR pathway. J Clin Oncol 2012; 30: 2919-28.